ESMO GI 2022 Highlights

CME

Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the ESMO World Congress on Gastrointestinal Cancer 2022

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 04, 2022

Expiration: October 03, 2023

Activity

Progress
1
Course Completed

References

  1. Tucatinib prescribing information. Bothell, WA: Seagen Inc.; 2022.
  2. Strickler J, Cercek A, Siena S, et al. Primary analysis of MOUNTAINEER: a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract LBA-2.
  3. Salem M, Kopetz S, El-Refai S, et al. Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC). Presented at: 2022European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract SO-34.
  4. Bullock A, Grossman J, Fakih M, et al. Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract LBA O-9.
  5. Waight JD, Chand D, Dietrich S, et al. Selective FcγR co-engagement on APCs modulates the activity of therapeutic antibodies targeting t cell antigens. Cancer Cell. 2018;33:1033-1047.e5.
  6. Bose CK. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer. Med Oncol. 2022;39:47.
  7. Dai Y, Zhao W, Yue L, et al. Perspectives on immunotherapy of metastatic colorectal cancer. Front. Oncol. 11:659964.
  8. Kim RD, Kovari BP, Martinez M, et al. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022;169:93-102.
  9. Patel MA, Kratz JD, Lubner SJ, et al. Esophagogastric cancers: integrating immunotherapy therapy into current practice. J Clin Oncol. 2022;24:2751-2762.
  10. Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449-462.
  11. Chau I, Ajani JA, Doki Y, et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648. Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract O-3.
  12. Zhang L, Geng Z, Hao B, et al. Tislelizumab: a modified anti-tumor programmed death receptor I antibody. Cancer Control. 2022;29:1-14.
  13. Yoon H, Kato K, Raymond E, et al. RATIONALE-306: randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC). Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract LBA1.
  14. Kam AE, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol. 2021;6:956-969.
  15. Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Presented at: 2022 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2022. Abstract 378.
  16. Durvalumab prescribing information. Wilmington, DE: AstraZeneca; 2022.
  17. He A, Valle J, Lee C, et al. Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study. Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract O-1.
  18. Abou-Alfa GK, Sahai V, Hollebecque, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671-684.
  19. Pemigatinib prescribing information. Wilmington, DE: Incyte Corporation; 2022.
  20. Vogel A, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202. Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract O-2.
  21. Goyal L, Kongpetch S, Crolley VE, et al. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021;95:102170.
  22. Puisieux MF, Pellat A, Assaf, et al. Therapeutic management of advanced hepatocellular carcinoma: an updated review. Cancers. 2022;14:2357.
  23. Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study. J Clin Oncol. 2021;39:2991-3001.
  24. Abou-Alfa, GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:Epub ahead of print.
  25. Vogel A, Chan S, Furuse J, et al. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study. Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract O-5.
  26. Demirtas CO, D’Alessio A, Rimassa L, et al. ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. 2021;3:100347.
  27. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol; 2020:6:e204564.
  28. Melero I, Yau T, Kang Y, et al. Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040. Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract LBA-7.
  29. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl J Med. 2020;382:1894-1905.
  30. Kelly RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:995-1008.
  31. Rimini M, Rimassa L, Kudo M, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international study. Presented at: 2022 European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract SO-14.